IPO Investing: What the First-Day Pop Really Means

The IPO Promise vs. The IPO Reality

IPO investing looks like a straightforward arbitrage: companies go public at a deliberately underpriced offering price, the stock jumps 15–20% on the first trading day, and patient observers conclude there's free money on the table. Decades of data back up the first part of that story. Research spanning 1983 to 2018 confirms that the overwhelming majority of IPOs rise on their opening day — often by 10–15%, and in hot markets by 50%, 80%, or more.

But the gap between that statistical average and what a real investor actually earns is where the IPO story gets complicated. Understanding that gap — and the specific frictions that create it — is the difference between a sophisticated IPO strategy and an expensive lesson in market structure.

Why Investment Banks Systematically Underprice IPOs

Underpricing isn't accidental. It's a deliberate feature of the traditional IPO process, and it serves multiple parties simultaneously.

Here's how the mechanics work: a private company approaches a lead investment bank, which assembles a syndicate and files a prospectus with financial regulators. The bank sets an initial offering price — but that price is explicitly a trial balloon, not a final figure. The bank then road-tests it with institutional investors. If demand looks strong, the price gets revised upward. If appetite is weak, it comes down.

The bank ultimately guarantees the offering price in exchange for an underwriting fee — typically a percentage of total IPO proceeds. To make that guarantee manageable, banks routinely shave 10–15% off their estimated fair value before setting the offering price. The company accepts this haircut, and the stock opens for trading at a built-in discount.

Why would a company agree to leave money on the table? Two reasons stand out:

• Founders and VCs are locked up. At most IPOs, only 5–10% of total shares are offered to the public. The rest remain with insiders, who typically face a 6–12 month lockup period before they can sell. A strong first-day pop generates positive press coverage and investor enthusiasm that can support the stock price by the time insiders are finally free to exit.
• The underpricing is concentrated on a small float. If you're offering 8% of the company at a 15% discount, the real cost to founders is roughly 1.2% of total company value — a modest price for the goodwill and media attention a successful IPO generates.

Notably, IPOs where the offering price was revised upward before listing tend to see larger first-day jumps than those where the price was revised downward. That revision direction is a signal worth tracking.

The Three Barriers Blocking Retail IPO Profits

Knowing that IPOs are systematically underpriced doesn't translate directly into a profitable strategy. Three structural barriers stand between that average 15–20% first-day return and what a typical investor actually captures.

1. Selection Bias: You Get What Nobody Wants

Imagine applying for 1,000 shares in every IPO coming to market. In practice, the shares you receive will be heavily skewed toward IPOs where demand is soft — meaning the ones most likely to be overpriced or to trade flat and down.

The mechanism is simple supply and demand. The IPOs that jump 50% on day one are massively oversubscribed. Institutional allocations eat up most of the supply; retail investors receive a tiny fraction of what they requested, sometimes as little as 20% of their order. The IPOs that disappoint? You get your full allocation — because not enough other investors wanted in.

Investment banks compound this by playing favourites. Preferred institutional clients — the large, repeat-business accounts — receive preferential allocations in the most attractive deals. An outsider applying for shares systematically ends up holding a portfolio overweighted in the duds.

2. The IPO Cycle Creates Famine Years

IPO volume is not a stable, consistent stream. It clusters intensely around bull markets. The late 1990s dot-com boom and the 2020–2021 post-pandemic surge produced enormous IPO volumes, with first-day returns averaging extraordinarily high figures. Fallow periods — recessions, bear markets, periods of elevated uncertainty — can see IPO counts collapse by 60–80% year over year.

An investment strategy built entirely around IPOs has no answer for famine years. Capital sits idle, or worse, gets deployed into lower-quality deals simply because they're available.

3. Long-Term Performance Is Weak — Often Negative

This is the finding that most IPO enthusiasm ignores. Academic research tracking IPO returns over 1, 2, 3, 4, and 5 years post-listing consistently shows that IPO portfolios underperform comparable non-issuing companies across every holding period.

In plain terms: investors who bought IPOs at the offering price, captured the first-day pop, and then held for five years often ended up behind investors who simply bought established public companies instead.

The implication is stark. IPO investing, if it is to generate alpha at all, is fundamentally a short-term strategy. The value window — to the extent one exists — is measured in days or months, not years. Investors who hold too long don't just fail to capture gains; they frequently give them back.

How the IPO Landscape Has Shifted

The classic IPO model is also under structural pressure from two directions.

Direct listings bypass the investment bank entirely. The company goes straight to the exchange; price discovery happens through open-market auction rather than a bank-managed process. Spotify and Coinbase used this route. Direct listings eliminate underwriting fees and the deliberate underpricing, but they also remove the price guarantee and the institutional sales effort.

SPACs (Special Purpose Acquisition Companies) take the opposite approach. A blank-check shell company raises cash through a public listing, then merges with a private target — effectively taking that private company public without a traditional IPO. SPAC volume surged dramatically in 2020–2021 before regulatory scrutiny and poor post-merger performance cooled enthusiasm significantly.

Both alternatives remain the exception. The bank-led IPO with its syndicate, prospectus, and price discovery roadshow is still the dominant mechanism — but its monopoly is eroding.

The composition of companies going public has also shifted materially. In the 1980s, a typical IPO candidate was a company with a proven, if small, business model that was already profitable — think early Apple or Microsoft. Today, companies stay private longer, scaling up on venture capital and increasingly from mutual funds and hedge funds that have entered the private markets. By the time they go public, they're larger in revenue terms but frequently unprofitable, with business models still in formation. The biotech and technology sectors exemplify this shift: companies raising hundreds of millions at IPO with years of losses ahead.

For investors, this raises the risk profile meaningfully. A bigger revenue number does not compensate for an unvalidated path to profitability.

What a Disciplined IPO Strategy Actually Looks Like

For investors who want to incorporate IPOs into a broader portfolio strategy — not as a core approach, but as a tactical allocation — three principles matter above everything else.

Do the fundamental work before the listing. Not all IPOs are created equal. The companies that jump on day one and continue to compound over 12–24 months share identifiable characteristics: clear competitive moats, credible paths to profitability, rational valuations relative to comparable public companies, and strong insider alignment. Applying basic valuation frameworks — discounted cash flow analysis, comparable company multiples, unit economics scrutiny — before subscribing is non-negotiable.

Tilt the allotment game in your favour. The selection bias problem is real but partially manageable. Building a relationship with a broker or institution that provides preferential allocations in high-demand deals materially improves expected outcomes. Retail investors who subscribe indiscriminately to every listing will consistently land in the worst deals.

Define your exit before you enter. Given the long-term underperformance data, entering an IPO without a clear sell discipline is accepting a known risk unnecessarily. Many professional IPO investors treat the position like a momentum trade: ride the initial enthusiasm, monitor for signs of fading buying pressure, and exit within 3–6 months rather than holding indefinitely. Note that some investment banks impose informal or formal restrictions on rapid flipping — understanding those terms before participating is essential.

The Bottom Line on IPO Investing

The 15–20% average first-day gain on IPOs is real, well-documented, and spans decades and geographies. What is equally real is that capturing it systematically is far harder than the headline number implies. Selection bias erodes the portfolio return. IPO cycles create periods of zero opportunity. And the multi-year return data is, bluntly, discouraging.

IPO investing can add value as a tactical, research-intensive component of a broader strategy — but it demands more rigour, not less, than buying established public companies. The investors who profit consistently from IPOs are not the ones chasing every listing. They are the ones who treat each IPO as a distinct valuation problem, manage their allocation strategy carefully, and enforce strict sell discipline on positions that have served their purpose.

The opportunity is real. The edge is narrow. The work required to find it is substantial.

---

This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial professional before making investment decisions.

Frequently Asked Questions

What is IPO underpricing and why does it happen? IPO underpricing refers to the practice of setting a company's offering price below its estimated market value, typically by 10–15%. Investment banks do this deliberately to ensure strong first-day demand and reduce the risk of a failed offering. The bank guarantees the offering price, so pricing conservatively limits its downside. The issuing company often accepts this because only a small percentage of shares — frequently under 10% — are sold to the public at IPO, making the real cost of underpricing relatively modest.

Why can't retail investors simply buy every IPO and profit from the first-day pop? Three structural barriers prevent this. First, selection bias: the most underpriced (best) IPOs are heavily oversubscribed, so retail investors receive very small allocations, while overpriced or weak IPOs fill orders completely. Second, IPO volume is cyclical — there are years with very few listings, leaving the strategy with no outlets. Third, long-term IPO performance is weak; studies show IPO portfolios underperform non-issuing comparable companies over 1–5 years, meaning investors who don't exit quickly often give back their gains.

How do direct listings differ from traditional IPOs? In a direct listing, a company bypasses the investment bank syndicate and lists shares directly on an exchange, where price is set by open-market supply and demand rather than a bank-managed process. This eliminates underwriting fees and the deliberate underpricing that characterises traditional IPOs, but it also removes the price guarantee and the institutional marketing effort that supports demand. Direct listings are used by companies with sufficient brand recognition to attract buyers without a traditional roadshow.

What has changed about the types of companies going public in recent decades? Companies are now going public later and at larger scale than in previous decades, partly because private capital markets — venture capital, late-stage growth funds, and even some mutual funds — can fund companies through stages that previously required public market access. The result is that today's typical IPO candidate is bigger by revenue but more likely to be unprofitable, with a less fully-formed business model. This increases risk for public market investors, particularly in technology and biotech, where companies may require years of additional investment before reaching profitability.